Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) have been given a consensus recommendation of "Moderate Buy" by the seven ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $7.81.
A number of equities analysts recently issued reports on DNA shares. BTIG Research boosted their price objective on Ginkgo Bioworks from $5.00 to $6.00 and gave the company a "buy" rating in a report on Tuesday, August 16th. Jefferies Financial Group dropped their price objective on Ginkgo Bioworks from $11.50 to $4.35 in a report on Thursday, June 16th. Finally, Raymond James boosted their price objective on Ginkgo Bioworks from $11.50 to $14.50 and gave the company an "outperform" rating in a report on Tuesday, August 16th.
Get Ginkgo Bioworks alerts:Ginkgo Bioworks Trading Down 4.2 %
DNA opened at $2.94 on Wednesday. The business has a fifty day moving average of $2.97 and a 200 day moving average of $3.06. Ginkgo Bioworks has a 52-week low of $2.09 and a 52-week high of $15.86. The company has a debt-to-equity ratio of 0.03, a quick ratio of 11.78 and a current ratio of 11.84.
Institutional Investors Weigh In On Ginkgo Bioworks
A number of institutional investors and hedge funds have recently bought and sold shares of the company. FDx Advisors Inc. bought a new position in shares of Ginkgo Bioworks in the 1st quarter worth $150,000. Exos Asset Management LLC raised its position in shares of Ginkgo Bioworks by 68.1% in the 1st quarter. Exos Asset Management LLC now owns 22,861 shares of the company's stock worth $92,000 after acquiring an additional 9,261 shares in the last quarter. Cubist Systematic Strategies LLC raised its position in shares of Ginkgo Bioworks by 315.2% in the 4th quarter. Cubist Systematic Strategies LLC now owns 1,156,832 shares of the company's stock worth $9,613,000 after acquiring an additional 878,232 shares in the last quarter. FNY Investment Advisers LLC raised its position in shares of Ginkgo Bioworks by 17.6% in the 2nd quarter. FNY Investment Advisers LLC now owns 102,680 shares of the company's stock worth $244,000 after acquiring an additional 15,375 shares in the last quarter. Finally, Wealthstream Advisors Inc. bought a new position in shares of Ginkgo Bioworks in the 1st quarter worth $378,000. 53.37% of the stock is owned by institutional investors.About Ginkgo Bioworks
(Get Rating)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
Further Reading
- Get a free copy of the StockNews.com research report on Ginkgo Bioworks (DNA)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
- Is Ford Rolling To A Rebound After Its Q3 Warning
- Has AMD stock stock fallen too far?
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
